Corrigendum to ‘Real-world use of protein C concentrate for the treatment of patients with protein C deficiency: an international registry’

The authors regret 3 errors in the published paper.In Table 1, the number of patients with severe congenital protein C deficiency (SCPCD) in the acute episode treatment and short-term replacement treatment categories were reported incorrectly.These values should be 4 (16%) and 2 (8%) for acute episode treatment and short-term replacement, respectively.The value for long-term prophylaxis in the Total column should also be 19 (44%).In Section 3.2, the percentage of historical treatment courses used for long-term prophylaxis in patients with SCPCD was reported incorrectly as 29%; the correct value is 30%.In the final sentence of the second paragraph in Section 3.7, the number of bleeding-related adverse events in patients with SCPCD was reported incorrectly.The sentence is corrected as follows:Three bleeding-related AEs (hematoma and hematuria) were reported in two patients with SCPCD, none of which were considered related to protein C concentrate.

Institutions

Publication Details

Journal
Journal of Thrombosis and Haemostasis
Published
2025-12-18
DOI
https://doi.org/10.1016/j.jtha.2025.12.001
Primary Topic
Blood Coagulation and Thrombosis Mechanisms
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Corrigendum to ‘Real-world use of protein C concentrate for the treatment of patients with protein C deficiency: an international registry’

Journal of Thrombosis and Haemostasis
Blood Coagulation and Thrombosis Mechanisms
article

Corrigendum to ‘Real-world use of protein C concentrate for the treatment of patients with protein C deficiency: an international registry’

article en

Abstract

The authors regret 3 errors in the published paper.In Table 1, the number of patients with severe congenital protein C deficiency (SCPCD) in the acute episode treatment and short-term replacement treatment categories were reported incorrectly.These values should be 4 (16%) and 2 (8%) for acute episode treatment and short-term replacement, respectively.The value for long-term prophylaxis in the Total column should also be 19 (44%).In Section 3.2, the percentage of historical treatment courses used for long-term prophylaxis in patients with SCPCD was reported incorrectly as 29%; the correct value is 30%.In the final sentence of the second paragraph in Section 3.7, the number of bleeding-related adverse events in patients with SCPCD was reported incorrectly.The sentence is corrected as follows:Three bleeding-related AEs (hematoma and hematuria) were reported in two patients with SCPCD, none of which were considered related to protein C concentrate.

Journal of Thrombosis and HaemostasisVol. 24(2)
Augusta University Health (US), Amalia Kinderziekenhuis (NL), Takeda (United States) (US), Takeda (Austria) (AT), University of Colorado Anschutz Medical Campus (US), Medical University of Vienna (AT)
Openalex Percentile: Top 38%
Blood Coagulation and Thrombosis Mechanisms
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.